advertisement

Topcon

Abstract #5631 Published in IGR 2-1

Effect of latanoprost or 8-iso prostaglandin E2 alone and in combination on intraocular pressure in glaucomatous monkey eyes

Wang RF; Podos SM; Serle JB; Mittag TW; Ventosa F; Becker B
Archives of Ophthalmology 2000; 118:74-77


OBJECTIVES: To evaluate the possible additivity of the effects of latanoprost and 8-iso prostaglandin E2 (8-iso PGE2) on intraocular pressure (IOP) in monkey eyes with laser-induced glaucoma. METHODS: The IOP was measured hourly for six hours beginning at 9:30 AM on day 1 (baseline day), days 6 and 7 (single-agent therapy), and days 13 and 14 (combination therapy with both agents). Following one day of baseline measurement, four monkeys with unilateral glaucoma received monotherapy) twice daily with either one drop of 0.005% latanoprost, or 0.1% 8-iso PGE2, 25 μl, at 9:30 AM and 3:30 PM from days 2 through 7. From days 8 through 14, both agents were applied twice daily five minutes apart. RESULTS: The maximum reduction of IOP (mean ± SEM) was 8.8±1.9 mmHg (26%) (p < 0.05) with latanoprost alone and 6.5±1.0 mmHg (21%) (p < 0.1) with 8-iso PGE2 alone, two hours after the morning dosing on day 7. A further reduction of IOP of 4.0±0.6 mmHg was produced when 8-iso PGE2 was added to latanoprost and of 3.0±0.7 mmHg was produced when latanoprost was added to 8-iso PGE2 on day 13 before the morning dosing. Combination therapy with both agents caused maximum IOP reductions from baseline of 11.3±3.0 mmHg (33%) (p<0.05) (latanoprost with 8-iso PGE2 added) and of 9.8±1.3 mmHg (31%) (p < 0.01) (8-iso PGE2 with latanoprost added) on day 14. CONCLUSION: Latanoprost and 8-iso PGE2 have an additive effect on IOP in glaucomatous monkey eyes. CLINICAL RELEVANCE: At least 50% of patients are treated with more than one ocular hypotensive medication. Thus, the determination of the additive effects on IOP of glaucoma medications will help to define optimum treatment regimens.

Dr. R.F. Wang, Department of Ophthalmology, Mount Sinai School of Medicine of New York University, New York, NY, USA


Classification:

5 Experimental glaucoma; animal models
11.4 Prostaglandins (Part of: 11 Medical treatment)



Issue 2-1

Change Issue


advertisement

Oculus